Drug info - Clinical applications of MAO-inhibitors

[Paracelsus]

A new entry has been added to Drugs Archive

Description:
Riederer et al. Current Medicinal Chemistry 2004;11:2033-43.

Abstract: Monoamine oxidase inhibitors (MAO-I) have been useful in the treatment of both psychiatric and
neurological disorders over centuries. Here we focus on the development of this drug treatment. Focus is given
on the use of irreversible MAO-I’s as well as on reversible ones. Benefit and side effects are reported for
Parkinson’s disease, Alzheimer’s dementia, depression syndrome and panic disorders. The preclinical and
clinical effects of selegiline with regard to neuroprotection are highlightened and the conclusion is drawn that
there is good evidence for a clinical neuroprotective capacity based on the assumption that the 50 percent
recovery of MAO-B is obtained already after a 10 days withdrawal of selegiline. There is also a focus on
selegiline's metabolism to amphetamine and methamphetamine. In order to avoid any such effects of metabolic
compounds on the cardiovascular system Zydis Selegiline, a melt-tablet avoid of major metabolism to
amphetamine and methamphetamine is described in detail.
Developments in MAO-I research are discussed in detail as there are moclobemide, lazabemide, rasagiline.
Interactions of MAO-I’ with tricyclics and serotonin selective reuptake inhibitors (SSRI’s) are described as
there is mentioning of interactions of MAO-I’s with other compounds in general. Tables and figures report on
clinical studies and on pharmacological properties of MAO-I’s.

To check it out, rate it or add comments, visit Clinical applications of MAO-inhibitors
The comments you make there will appear in the posts below.